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Abstract. 
Sarcomatous hepatocellular carcinoma (HCC) is a rare subtype of hepatoma, along with 
worse prognosis than ordinary HCC. The risk of this subtype is still unknown, but some be-
lieved it has to be related to post anti-cancer therapy. 
We reported a case of sarcomatous HCC and the patient did not receive any anti-cancer 
therapy before. He came to our outpatient department due to symptoms of generalized malaise 
and poor appetite. One 10 cm in sized tumor was detected by ultrasound. He received surgical 
resection of the tumor but the tumor recurred after 3 months, with multiple metastases to peri-
toneum and brain. However, even under aggressive treatment, patient still expired in 6 months 
after operation.  
We reviewed several reports of this subtype of HCC. It was known that sarcomatous HCC 
is hard to be distinguished with ordinary HCC before surgery. There is no evidence that adju-
vant therapy including chemotherapy, radiotherapy and target therapy may improve the survival 
rate. It would usually be diagnosed as atypical HCC and treated as ordinary HCC, however, the 
prognosis is much worse; this sarcomatosis type HCC should be seriously considered. 
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中文摘要 
  我們報告一個臨床上較為罕見的病例，一個 65 歲男性有慢性 B 型肝炎但卻沒有規則
追蹤，因為食慾不振且體重減輕去門診求診時意外發現一 10 公分大的肝臟腫瘤。電腦斷
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層並沒有明顯的動脈相顯影及非動脈性不顯影等典型肝癌的特徵。AFP 有升高所以臨床
上還是認為疑似肝癌。經開刀切除後病理證實為一種具有肉瘤變化的肝癌 – Hepatoma 
with sarcomatous change。此病患在開完刀三個月後腫瘤就復發，且多處轉移至腹腔及腦
部，雖然經積極治療包括標靶藥物 Nexavar 及電療，病患依舊於手術後 6 個月死亡。 
  討論部分提到，這種肝癌據過去統計占所有肝癌的 5-14%，預後極差。相比一般的肝
癌，有肉瘤變化的肝癌也有較高的肝外轉移率及肝門靜脈侵犯的機率、較低的 2 年存活
率及肝移植機率。遺憾的是，此種患者在用傳統診斷肝癌的工具如超音波，AFP、電腦斷
層甚至核磁共振上都沒有太專一性的表現可以與一般的肝癌鑑別。只有一篇文章由 Ijichi
在 2012年提到用 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)可以在術
前鑑別肝癌是否有肉瘤變化。但這部分還需要更多研究去證實。 
 
關鍵字: 肝細胞癌 c 肉瘤狀變化 
 
INTRODUCTION 
It is known that hepatocellular carcinoma (HCC) 
may present with various histological features and has 
several subtypes, such as scirrhous HCC, fibrolamel-
lar carcinoma, combined HCC-cholangiocarcinoma 
(HCC-CC), sarcomatoid HCC, undifferentiated carci-
noma, and lymphoepithelioma-like HCC.  
These subtypes of HCC have variable clinical 
manifestation and growth rates. Sarcomatosis is one 
subtype of HCC, which has been reported sporadically 
before. Its clinical character is difficult to distinguish 
from ordinary HCC’s, such as symptoms, elevated 
Alpha FetoProtein, or by abdominal sonography. Dy-
namic Computed tomography or MRI usually shows 
hepatic mass without typical HCC characteristic and 
they were frequently mis-diagnosed as atypical HCC. 
The correct diagnosis usually was made by pathology 
after operation. However, the prognosis of sarcoma-
tous HCC is much poorer than ordinary type or any 
other subtypes of HCC. Rapid recurrence with high 
distant metastasis rate would be noted soon after op-
eration. Survival length may not even make to 6 
months. 
   We reported this case to remind clinical physicians 
the characters and clinical progress of this subtype of 
HCC. Poor prognosis should be mentioned when di-
agnosis confirmed. We also discussed the possibility 
of image diagnosis before pathologic studies. 
 
CASE REPORT 
A 65-year-old male had history of hepatitis B in-
fection without regular follow up. He worked in China 
for a long time and suffered from poor appetite and 
weight loss about 10 kg in one month and visited a 
local hospital. Abdominal ultrasound showed a mix 
echoic lesion in the left liver, size about 10.2*6.8 cm, 
suspected to be malignancy and he was transferred to 
our hospital. When admitted, physical examination 
showed mild distention of the abdomen without ten-
derness. HBsAg and Anti-HBeAg were both negative. 
AFP was 183 ng/ml (Reference range < 10 ng/ml). 
Abdominal CT showed a heterogeneous hypodense 
tumor in the left lobe of liver (size about 11*8.8 cm) 
with peripheral contrast enhancement in arterial and 
portal phases but without peripheral contrast en-
hancement in delay phase. No regional lymphade-
nopathy is shown in CT scan (Figure 1A). Clinical 
stage is T3aN0M0 (stage IIIa) in TNM classification 
system. Persistent fever (>38˚C), leukocytosis, WBC 
20200 /uL (Reference range 4000~10000 / uL) and 
high CRP level, 16.79 mg/dl (Reference range < 0.80 
mg/dl) were found during hospitalization. Surgical 
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Figure 1. (A) CT scan of liver after enhancement on portal phase revealed a hypodense mass in the left lobe of 
liver before surgery. (B) CT scan of liver after enhancement on portal phase revealed multiple recurrent 
tumors and another small one in the right lobe of liver 3 months after surgery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. CT scan of brain with enhancement revealed 
an enhanced nodular lesion with perifocal 
edema at junction of right frontal and parie-
tal lobes 
 
excision of the left hepatic tumor by total left lobec-
tomy was done smoothly and then fever subsided. The 
pathology showed multiple spindle shaped cells (Fig-
ure 3B) and multiple typical HCC cells (Figure 3A), 
which suggested both characters of sarcoma and he-
patoma in this tumor. Furthermore, the sarcomatous 
component is diffusely positive for Vimentin stain 
(Figure 3C) and focally positive for HepPar-1 (Figure 
3D), which proved the sarcomatous part is originating 
from hepatocellular carcinoma rather than from other 
origin or primary sarcoma. Surgical free margin is 5 
mm. 
The HCC grading is Grade IV. One major branch 
of portal vein is involved. The stage of fibrosis in the 
non-tumor part is none to moderate fibrosis (Ishak 
score 0-4) (F2). The Necroinflammatory score of 
non-tumor part is 12/18, calculated by MODIFIED 
HAI GRADING system (Moderate piecemeal necrosis: 
3, Zone 3 necrosis with occasional portal-central (P-C) 
bridging:4, five to ten foci focal (spotty) lytic necrosis, 
apoptosis and focal inflammatory per 10x objective: 3, 
moderate portal inflammation:2). 
AFP declined to 6.39 ng/ml (Reference range < 10  
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Figure 3. (A) Epithelioid cells with abundant cytoplasm and high grade nuclei (H&E 200X). (B) Proliferation of 
malignant spindle cells with tumor necrosis (Left upper part, Arrow area) (H&E 200X). (C) Malignant 
spindle cells are diffusely positive for vimentin immunohistochemical stain (200X). (D) Some tumor 
cells are positive for HepPar-1 immunohistochemical stain (200X) 
 
 
ng/ml) after surgery and he was discharged under sta-
ble condition. Further treatment including chemo-
therapy or target therapy was not initiated right after 
surgery due to the National Health Insurance policy in 
Taiwan and patient’s economic condition. 
However, three months later, abdominal CT was 
arranged again and showed multiple recurrent tumors 
in right liver and abdominal cavity (Figure 1B). Left 
lower leg weakness was also mentioned and brain CT 
showed a possible metastatic lesion in the junction of 
right frontal lobe and parietal lobe (Figure 2). The 
patient had received target therapy (Sorafenib) 800 mg 
per day and radiotherapy for brain metastasis but the 
response was poor. He expired about six months after 
surgery.  
 
DISCUSSION 
Sarcomatous hepatocellular carcinoma (HCC) is 
very rare but gradually increasing in prevalence dur-
ing recent dozen years. Study by Kojiro had revealed 
that sarcomatous HCC accounted for 5.9% of total 
HCC during the 12 years from 1969 to 1980, and 
A B
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14.3% of total HCC during the 6 years from 1983 to 
1989 [1].  
The cause of increasing incidence is hard to 
know because of the low incidence of sarcomatous 
HCC, but some believed it was related to anti-cancer 
therapy such as trans-arterial embolization (TAE), 
percutaneous ethanol injection therapy (PEIT) and 
even radiofrequency ablation (RFA) [1-3]. For exam-
ple, a study published by Kojiro in 1989, analyzing 
579 autopsy cases of hepatocellular carcinoma (HCC), 
with 55 cases (9.4%) exhibited a sarcomatous appear-
ance. They found sarcomatous appearance in 20.9% of 
the cases undergoing anticancer therapy and in 4.2% 
of the cases not undergoing anticancer therapy [1]. 
It is hard to diagnose this subtype of HCC before 
pathology. Two previous studies before 2010 even 
claimed that there is no way except biopsy to distin-
guish between sarcomatous and ordinary HCC [4,5]. 
Fortunately, some image characters of sarcomatous 
HCC were under analyzed. For example, typical sar-
comatosis HCC in dynamic CT usually showed pe-
ripheral enhancement with an unenhanced central por-
tion, compatible with the fibrous stroma in the periph-
ery and central necrosis in the tumor [6]. Typical MRI 
would show a mass with low T1 and high T2 signal 
intensity, with some intratumoral cystic lesions [7]. A 
Japanese author H. Honda published a study in 1996, 
compare the image character of sarcomatous HCC and 
ordinary HCC by analyzing 6 sarcomatous HCC pa-
tients. All these tumors had peripheral enhancement 
on delayed CT images. Lymphadenopathy was ob-
served in 100% (six of six patients) and intrahepatic 
metastases were observed in 83% (five of six). Both 
metastatic lesions had peripheral enhancement, just 
like their primary hepatic tumors. Although peripheral 
enhancement on early CT images could also be ob-
served in hemangiomas (56%), metastases (29%), and 
in intrahepatic cholangiocarcinomas(15%), however, 
the peripheral enhancement on delayed CT images 
was more commonly seen in sarcomatous HCC (100%) 
than in those other tumors (18%, 11%, 5%) [8]. Be-
sides, some other image tools used to distinguish sar-
comatous HCC to ordinary HCC were also applied 
clinically. One recent study by Ijichi in 2012 had 
mentioned that 18F-fluorodeoxyglucose positron emis-
sion tomography (FDG-PET) was a good tool to de-
tect sarcomatous HCC. In his study, maximum stand-
ardized uptake value (SUVmax) of sarcomatous 
hepatocellular carcinoma is higher. This above finding 
may be useful in differentiating HCCSC from com-
bined hepatocellular and cholangiocarcinoma, undif-
ferentiated HCC, moderately and poorly differentiated 
HCC. High SUV max values represented poor prog-
nosis. Although the expansive cost and not popularity 
of FDG-PET limited the clinical application in 
worldwide, however, FDG-PET could be considered 
as an effective and non-invasive tool to evaluate the 
aggressiveness of primary HCC with typical CT or 
MRI findings [6].  
Pathology of sarcomatous HCC usually reveals 
sarcomatous appearance include anaplastic spindle- 
shaped cells forming interlacing bundles with a partial 
storiform pattern. The spindle-shaped cells have an 
eosinophilic cytoplasm, ovoid or long nuclei, with 
marked anisocytosis and frequent mitoses [9]. 
Currently, treatment of sarcomatous HCC is simi-
lar to ordinary HCC but the prognosis of sarcomatous 
HCC is much worse. As previous studies revealed, 
sarcomatous HCC had higher rate of extrahepatic me-
tastases (46%) and portal invasion (62%) than ordi-
nary HCC [9,10]. 2-year survival rate after resection 
(25%) and liver transplantation (33%) were also low 
in patients of sarcomatous HCC within the Milan cri-
teria [4].  
Radical resection of early stage tumor seemed to 
be the best treatment for sarcomatous HCC. Trans- 
arterial embolization (TAE), trans-arterial chemo-
therapy embolization (TACE) or hepatic arterial infu-
sion chemotherapy (HAIC) is not considered to be 
effective due to poor vascularity and poor enhance-
ment in CT arterial phase. Kato, Y., K. had reported 
one case in 2011, who had a huge hepatoma with 
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focal sarcomatous change receiving HAIC (using 5- 
fluorouracil and cisplatin). Poor response was noted 
and patient died in 8 months after diagnosis [11].  
The role of systemic adjuvant chemotherapy is 
still under debated. Tsuji, Y., K. had reported one case 
of sarcomatosis HCC, with a 23 x 13 x 23 cm tumor, 
originated from segments IV and VII of the liver, and 
grew extrahepatically. Right side diaphragm infiltra-
tion was also noted during operation. Resection of the 
involved segment and diaphragm was performed and 
they arranged combination chemotherapy (etoposide, 
epirubicin, and cisplatin). No recurrence for 12 
months after surgery was noted [12]. Although one 
case report may not make this systemic chemotherapy 
as a standard treatment, frustratingly, there is no better 
way for treatment currently so far. 
We reported one patient with sarcomatous HCC. 
And we might try this regimen in the next feasible 
case. 
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